NO991194D0 - Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid - Google Patents
Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydrokloridInfo
- Publication number
- NO991194D0 NO991194D0 NO991194A NO991194A NO991194D0 NO 991194 D0 NO991194 D0 NO 991194D0 NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 D0 NO991194 D0 NO 991194D0
- Authority
- NO
- Norway
- Prior art keywords
- alfa
- methoxyimino
- azabicyclo
- oct
- controlled
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
| PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991194D0 true NO991194D0 (no) | 1999-03-11 |
| NO991194L NO991194L (no) | 1999-03-11 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991194A NO991194L (no) | 1996-09-12 | 1999-03-11 | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (no) |
| JP (1) | JP2001500150A (no) |
| KR (1) | KR20000036039A (no) |
| CN (2) | CN1235544A (no) |
| AR (1) | AR008176A1 (no) |
| AU (1) | AU724086B2 (no) |
| BR (1) | BR9711734A (no) |
| CA (1) | CA2265661A1 (no) |
| CO (1) | CO5031291A1 (no) |
| CZ (1) | CZ83299A3 (no) |
| GB (1) | GB9619074D0 (no) |
| HU (1) | HUP9904401A3 (no) |
| ID (1) | ID19589A (no) |
| IL (1) | IL128781A0 (no) |
| MA (1) | MA24359A1 (no) |
| NO (1) | NO991194L (no) |
| NZ (1) | NZ334268A (no) |
| PE (1) | PE2499A1 (no) |
| PL (1) | PL332074A1 (no) |
| TR (1) | TR199900505T2 (no) |
| WO (1) | WO1998010762A2 (no) |
| ZA (1) | ZA978133B (no) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| JP2002506031A (ja) | 1998-03-11 | 2002-02-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 組成物 |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| EP1617838A4 (en) * | 2003-04-25 | 2011-07-06 | Mitsubishi Tanabe Pharma Corp | COMPOSITION FOR ORAL ADMINISTRATION WITH ALKYLENEDIOXYBENZOLE DERIVATIVES |
| ES2273271T5 (es) * | 2003-05-14 | 2013-05-21 | Aptalis Pharma Limited | Composición de liberación controlada de fármaco resistente a la tensión mecánica in vivo |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| SG164375A1 (en) * | 2004-08-13 | 2010-09-29 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| DE602005024570D1 (de) | 2004-08-13 | 2010-12-16 | Boehringer Ingelheim Pharma | Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| CN114901272A (zh) * | 2019-04-19 | 2022-08-12 | 霍夫曼技术有限责任公司 | 持续释放制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0392803B1 (en) * | 1989-04-13 | 2004-06-16 | Beecham Group p.l.c. | Novel compounds |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Ceased
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Ceased
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194L/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CZ83299A3 (cs) | 1999-08-11 |
| BR9711734A (pt) | 1999-08-24 |
| CO5031291A1 (es) | 2001-04-27 |
| ID19589A (id) | 1998-07-23 |
| CA2265661A1 (en) | 1998-03-19 |
| GB9619074D0 (en) | 1996-10-23 |
| HUP9904401A3 (en) | 2001-03-28 |
| CN1235544A (zh) | 1999-11-17 |
| HUP9904401A2 (hu) | 2000-06-28 |
| IL128781A0 (en) | 2000-01-31 |
| KR20000036039A (ko) | 2000-06-26 |
| EP0929301A2 (en) | 1999-07-21 |
| MA24359A1 (fr) | 1998-07-01 |
| PE2499A1 (es) | 1999-03-24 |
| NZ334268A (en) | 2000-10-27 |
| JP2001500150A (ja) | 2001-01-09 |
| WO1998010762A3 (en) | 1998-06-04 |
| WO1998010762A2 (en) | 1998-03-19 |
| AU4128897A (en) | 1998-04-02 |
| PL332074A1 (en) | 1999-08-30 |
| CN1446535A (zh) | 2003-10-08 |
| AR008176A1 (es) | 1999-12-09 |
| NO991194L (no) | 1999-03-11 |
| TR199900505T2 (no) | 1999-06-21 |
| AU724086B2 (en) | 2000-09-14 |
| ZA978133B (en) | 1999-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991194D0 (no) | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid | |
| IL145071A0 (en) | Fused ring compounds and pharmaceutical compositions containing the same | |
| DE69514087D1 (de) | Pharmazeutisch aktive substituierte aromatische verbindungen | |
| IL137445A0 (en) | Pharmaceutically active compounds and methods of use thereof | |
| NO990944L (no) | Tablett med kontrollert frigivelse av alfuzosinhydroklorid | |
| HUP0004926A3 (en) | 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring, pharmaceutical compositions containing them and their use | |
| EA200200571A1 (ru) | Новая композиция и ее применение | |
| PL356769A1 (en) | Novel heterocyclic compounds and salts thereof and medicinal use of the same | |
| HU9800112D0 (en) | Biphenyl-sulfonyl-substituted heterocyclic compounds of fife-membered ring, their production and use | |
| HUP9901590A3 (en) | Substituted aza- and diazacycloheptane and cyclooctane derivatives, use thereof, pharmaceutical compositions containing these compounds | |
| EA200200119A1 (ru) | β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ | |
| EP1115396A4 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF | |
| HUP9902166A3 (en) | Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds | |
| ES2171018T3 (es) | Uso de agentes inmunomoduladores. | |
| NO986086D0 (no) | FremgangsmÕte for fremstilling av 17-estere av 9<alfa>,21-dihalo-pregnan-11 | |
| EE200100656A (et) | Kristallilise asabitsüklo(2,2,2)oktaan-3-amiintsitraadi polümorfid ja nende ravimsegud | |
| ITMI911604A0 (it) | Procedimento per la preparazione della n- (2,6-diclorofenil) -n-feniln- (cloroacetil) - ammina | |
| NO992668D0 (no) | Topisk preparat for innf°ring av farmas°ytisk aktive peptidforbindelser i levende organismer | |
| NO910372L (no) | Fremgangsmaate for fremstilling av heksahydropyrrolo(2,3-b)indolkarbamater-, urea-, amider og beslektede forbindelser og deres anvendelse som medikamenter. | |
| ATE232103T1 (de) | Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| NO20010195D0 (no) | Fremgangsmåte for behandling | |
| GB9821966D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim | |
| GB9821967D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim | |
| HK1021336A (en) | Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride |